Reports preliminary Q2 adjusted SG&A expense $294M.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Sarepta put volume heavy and directionally bearish
- Sarepta price target lowered to $28 from $30 at JPMorgan
- Sarepta Therapeutics: Overcoming Setbacks with Promising Long-term Potential
- Sarepta Faces Legal Storm Over ELEVIDYS Trial Risks
- FDA flags possible safety signals in new report, says RBC Capital